9 May 2024
GEIGER COUNTER
LIMITED
(THE
"COMPANY")
Exercise
of outstanding Subscription Share Rights
Geiger Counter Limited announces
that further to the announcement on 7 May 2024, the Subscription
Trustee has exercised all of the 5,816,025 outstanding Subscription
Rights (the "Rump"). The ordinary shares of no par value in
the capital of the Company ("Ordinary Shares") that arose from the
exercise of the Rump have been sold by Cavendish Capital Markets
Limited by way of a secondary market placing, raising total gross
proceeds for the Company of £2.2 million. After deduction of
the cost of exercising the Subscription Rights of the Rump and all
the costs and expenses of the Subscription Trustee, the Registrar
and the secondary market placing, any resultant net proceeds will
be distributed by the Registrar to the holders of the Rump in
proportion to their Shareholding on the Record Date by 31 May
2024.
Following the exercise of all
Subscription Rights, the Company has raised a total of £6.8
million. The funds raised will be invested in a manner
consistent with the stated investment objectives of the
Company.
Accordingly, the Company announces
that it will be issuing and allotting a further 5,816,025 Ordinary
Shares, pertaining to the outstanding Subscription Rights exercised
by the Subscription Trustee, subject to admission to trading.
Application will be made for the new Ordinary Shares to be
admitted to trading on TISE and dealings on LSE SETSqx. It is
expected that dealings in the new Ordinary Shares will commence at
8.00 a.m. on 10 May 2024.
Total Voting Rights
For the purposes of the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules
("DTRs"), following Admission the issued ordinary share capital of
the Company will consist of
144,199,804
Ordinary Shares with voting rights attached and 8,474,445 Ordinary
Shares in treasury. This figure of 144,199,804 Ordinary
Shares may be used by the Company's shareholders as the denominator
for the calculation by which they will determine whether they are
required to notify their interest in, or a change to their interest
in, the share capital of the Company under the DTRs.
The information contained within
this RNS is considered to be inside information prior to its
release.
For further information, please
contact:
Manulife | CQS Investment Management
|
Craig Cleland
|
T: +44 (0) 20 7201 5368
|
Cavendish Capital Markets Limited
|
Tunga Chigovanyika / Will
Talkington (Corporate Finance)
|
T: +44 (0) 20 7397 1915
|
|
Daniel Balabanoff / Pauline Tribe
(Sales)
|
T: +44 (0) 20 7220 0500
|
R&H Fund Services (Jersey) Limited
|
Jane De Barros
|
T :+44 (0) 1534 825 259
|